BCAB Документы SEC - BioAtla, Inc.- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

CIK

1826892

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioAtla, Inc.

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

August 7, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 7, 2025	EX-99.1	BIOATLA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS Exhibit 99.1 BIOATLA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 – Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; meeting planned with U.S. Food & Drug Admi
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
August 7, 2025	EX-10.1	Lease Agreement between BioAtla, Inc. and HCP Torreyana, LLC, as amended. Exhibit 10.1 Certain information in this document identified by brackets [***] has been omitted because it is both (i) not material and (ii) the type that BioAtla, Inc. customarily and actually treats as private and confidential. 11085 TORREYANA ROAD LEASE This Lease (this “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is mad
June 20, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 16, 2025	424B3	BIOATLA, INC. Up to 9,679,158 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-287011 BIOATLA, INC. Up to 9,679,158 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants This prospectus relates to the resale from time to time, by the selling securityholders (which term as used in this prospectus includes their transferees, pledgees, distributees, donees and successors-in-interest) identif
May 16, 2025	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 12, 2025	CORRESP	11085 Torreyana Road San Diego, CA 92121 11085 Torreyana Road San Diego, CA 92121 May 12, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller, Office of Life Sciences Re: BioAtla, Inc. Registration Statement on Form S-3 Filed May 6, 2025 File No. 333-287011 REQUEST FOR ACCELERATION OF EFFECTIVENESS Acceleration Request Requested Date: May
May 6, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2025 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
May 6, 2025	EX-99.1	BIOATLA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS BIOATLA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026 – Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year l
May 6, 2025	EX-FILING FEES	Filing fee table EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Table Form S-3 (Form Type) BioAtla, Inc.
May 6, 2025	S-3	As filed with the Securities and Exchange Commission on May 6, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 6, 2025 Registration No.
April 24, 2025	DEF 14A	INFORMATION ABOUT SOLICITATION AND VOTING INTERNET AVAILABILITY OF PROXY MATERIALS QUESTIONS AND ANSWERS ABOUT THE MEETING BOARD OF DIRECTORS AND CORPORATE GOVERNANCE NOMINATIONS PROCESS AND DIRECTOR QUALIFICATIONS PROPOSAL ONE: ELECTION OF DIRE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section (a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definiti
April 24, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 28, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioAtla, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value pe
March 28, 2025	EX-19.1	Insider Trading Policy of BioAtla, Inc. Exhibit 19.1 BioAtla, Inc. Insider Trading Policy Federal and state securities laws prohibit the purchase or sale of a company’s securities by persons who are aware of material information about that company that is not generally known or available to the public. These laws also prohibit persons who are aware of such material nonpublic information from disclosing this information to others who may
March 28, 2025	EX-4.3	Exhibit 4.3 Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 BioAtla, Inc. (“we,” “our,” “us,” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following summary of the terms of our common stock is based upon our restated certificate
March 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-3978
March 28, 2025	S-8	As filed with the Securities and Exchange Commission on March 27, 2025 As filed with the Securities and Exchange Commission on March 27, 2025 Registration No.
March 27, 2025	EX-99.1	BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 – Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS N
March 27, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
February 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 06, 2025 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Nu
January 24, 2025	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tm254389d1ex-1.htm EXHIBIT I EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.0001 per share, of BioAtla, Inc. will be filed on behalf of each of the p
December 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 BIOATLA, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Nu
December 20, 2024	EX-99.1	Important Notices & Disclaimers This presentation (the “Presentation”) by BioAtla, Inc. (“we”, “us”, “our”, “BioAtla”, or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 Exhibit 99.1 Conditionally Active Biologics: Transforming Cancer Therapy Investor Presentation Non-Confidential December 2024 Important Notices & Disclaimers This presentation (the “Presentation”) by BioAtla, Inc. (“we”, “us”, “our”, “BioAtla”, or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business
December 20, 2024	EX-10.1	Form of Securities Purchase Agreement, dated as of December 19, 2024 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 19, 2024, between BioAtla, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and
December 20, 2024	424B5	9,679,158 Shares of Common Stock Warrants to Purchase up to 9,679,158 Shares of Common Stock Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-262528 PROSPECTUS SUPPLEMENT (To Prospectus dated May 18, 2022) 9,679,158 Shares of Common Stock Warrants to Purchase up to 9,679,158 Shares of Common Stock Common Stock Warrants We are offering 9,679,158 shares of our common stock, together with warrants to purchase 9,679,158 shares of common stock to certain institutional investors in a registered direct offering pursuant to this prospectus supplement and the accompanying prospectus and a securities purchase agreement with such investors.
December 20, 2024	EX-99.1	BIOATLA, INC. ANNOUNCES REGISTERED DIRECT OFFERING TO ADVANCE TWO MID-STAGE CLINICAL PROGRAMS TO KEY INFLECTION POINTS Exhibit 99.1 BIOATLA, INC. ANNOUNCES REGISTERED DIRECT OFFERING TO ADVANCE TWO MID-STAGE CLINICAL PROGRAMS TO KEY INFLECTION POINTS SAN DIEGO, Calif., December 20, 2024 – BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, t
December 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 BIOATLA, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Nu
December 20, 2024	EX-4.1	Form of Warrant Exhibit 4.1 COMMON STOCK PURCHASE WARRANT BIOATLA, INC. Warrant Shares: Initial Exercise Date: June 20, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after June 20, 2025 (the “Initial Exercise
November 14, 2024	SC 13G/A	BCAB / BioAtla, Inc. / TANG CAPITAL MANAGEMENT LLC - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 bcab1015240sc13ga3.htm AMENDMENT NO. 3 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* BioAtla, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09077B104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appr
November 7, 2024	EX-99.1	BIOATLA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS BIOATLA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months (ongoing) in a heavily pretreated population; actionable feedback received from the U.
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
November 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Nu
October 2, 2024	SC 13D/A	BCAB / BioAtla, Inc. / Soleus Private Equity Fund I, L.P. - AMENDMENT NO. 6 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6) BioAtla, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 09077B104 (CUSIP Number) Soleus Private Equity GP I, LLC 104 Field Point Road, 2nd Floor Greenwich, CT 06830 Attn: Steven J. Musumeci (475) 208-3178 (Name, Add
September 23, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File N
September 23, 2024	EX-10.2	Global Transaction Agreement between BioAtla, Inc. and Himalaya Therapeutics SEZC, dated as of September 23, 2024 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXHIBIT 10.
September 23, 2024	EX-10.1	License Agreement between BioAtla, Inc. and Context Therapeutics Inc., dated as of September 23, 2024 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXHIBIT 10.
September 6, 2024	SC 13D/A	BCAB / BioAtla, Inc. / Soleus Private Equity Fund I, L.P. - AMENDMENT NO. 5 TO SCHEDULE 13D Activist Investment SC 13D/A 1 ea0213812-13da5sole1bio.htm AMENDMENT NO. 5 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5) BioAtla, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 09077B104 (CUSIP Number) Soleus Private Equity GP I, LLC 104 Field Point Road, 2nd Floor
August 8, 2024	EX-99.1	BIOATLA REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS BIOATLA REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024 – Evalstotug (CAB-CTLA-4 antibody) demonstrated a similar low incidence and severity of immune-related adver
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
August 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 8, 2024	EX-10.1	Amended and Restated Director Compensation Policy Exhibit 10.1 BIOATLA, INC. DIRECTOR COMPENSATION POLICY (As amended and restated on June 13, 2024) Each member of the Board of Directors (the “Board”) of BioAtla, Inc. (the “Company”), who is not an employee of the Company (each such member, a “Non-Employee Director”), will receive the compensation described in this Director Compensation Policy (the “Director Compensation Policy”) for his or her B
August 8, 2024	EX-10.2	Form of Non-Employee Director Restricted Stock Unit Agreement Exhibit 10.2 RESTRICTED STOCK UNIT AGREEMENT UNDER THE BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN THIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”) is between BioAtla, Inc., a Delaware corporation (the “Company”), and See Third-Party Administrative Platform (the “Grantee”) and is made as of See Third-Party Administrative Platform (the “Grant Date”). RECITALS WHEREAS, the Company maintains the
August 7, 2024	SC 13G	BCAB / BioAtla, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BIOATLA, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 09077B104 (CUSIP Number) AUGUST 5, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sc
June 13, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 17, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 14, 2024	EX-10.1	China Clinical Trial Services Agreement, dated April 8, 2022, by and between BioAtla, Inc. and Himalaya Therapeutics Limited Company, as amended Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***].” CHINA CLINICAL TRIAL SERVICES AGREEMENT This China Clinical Trial Services Agreement (“Agreement”), made as of this 8th day of April 2022 (the “Effective Date”),
May 14, 2024	EX-99.1	BIOATLA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS BIOATLA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024 – Evalstotug (CTLA-4 antibody) Phase 1 study progressing well, anticipate clearing dose-limiting toxicity (DLT) observation period with 1 gram (14.
May 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
May 14, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 14, 2024	EX-10.2	Form of Restricted Stock Unit Agreement Exhibit 10.2 RESTRICTED STOCK UNIT AGREEMENT UNDER THE BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN THIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”) is between BioAtla, Inc., a Delaware corporation (the “Company”), and See Third-Party Administrative Platform (the “Grantee”) and is made as of See Third-Party Administrative Platform (the “Grant Date”). RECITALS WHEREAS, the Company maintains the
April 24, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 24, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section (a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section (a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definiti
April 24, 2024	EX-3.1	Amended and Restated Bylaws of BioAtla, Inc. AMENDED AND RESTATED BYLAWS OF BIOATLA, INC. (the “Corporation”) As adopted on and effective as of April 22, 2024 ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place, which shall be fixed or subsequently changed any time by the vote of the Board of
April 24, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 16, 2024	SC 13D/A	BCAB / BioAtla, Inc. / Soleus Private Equity Fund I, L.P. - AMENDMENT NO. 4 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4) BioAtla, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 09077B104 (CUSIP Number) Soleus Private Equity GP I, LLC 104 Field Point Road, 2nd Floor Greenwich, CT 06830 Attn: Steven J. Musumeci (475) 208-3178 (Name, Add
March 26, 2024	EX-10.25	Form of Employee Stock Option Agreement Exhibit 10.25 Stock Option No: Stock Option STOCK OPTION AGREEMENT UNDER THE BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN THIS STOCK OPTION AGREEMENT (this “Agreement”) is between BioAtla, Inc., a Delaware corporation (the “Company”), and (the “Grantee”). RECITALS WHEREAS, the Company maintains the BioAtla, Inc. 2020 Equity Incentive Plan (as it may be amended and/or restated from time to time, the “P
March 26, 2024	S-8	As filed with the Securities and Exchange Commission on March 26, 2024 As filed with the Securities and Exchange Commission on March 26, 2024 Registration No.
March 26, 2024	EX-97.1	Compensation Recovery Policy of BioAtla, Inc. Exhibit 97.1 bioatla, INC. COMPENSATION RECOVERY POLICY (Adopted and approved on September 14, 2023 and effective as of October 2, 2023) 1. Purpose BioAtla, Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Company has ad
March 26, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-3978
March 26, 2024	EX-10.17	First Amendment to Lease with HCP Torreyana, dated January 16, 2019 Exhibit 10.17 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (this "First Amendment") is made and entered into as of the 16th day of January, 2019, by and between HCP TORREYANA, LLC, a Delaware limited liability company ("Landlord"), and BIOATLA, LLC, a Delaware limited liability company ("Tenant"). R E C I T A L S : A. Landlord and Tenant entered into that certain Lease dated June 2, 2017
March 26, 2024	EX-99.1	BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination with pembrolizumab in 2H 2024 – CAB-ROR2 (BA3021) Phase 2 melanoma and squamous cell carcinoma of the
March 26, 2024	EX-10.24	Form of Non-Employee Director Stock Option Agreement Exhibit 10.24 Stock Option No: Stock Option STOCK OPTION AGREEMENT UNDER THE BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN THIS STOCK OPTION AGREEMENT (this “Agreement”) is between BioAtla, Inc., a Delaware corporation (the “Company”), and (the “Grantee”). RECITALS WHEREAS, the Company maintains the BioAtla, Inc. 2020 Equity Incentive Plan (as it may be amended and/or restated from time to time, the “P
March 26, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 26, 2024	EX-4.3	Description of Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 BioAtla, Inc. (“we,” “our,” “us,” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following summary of the terms of our common stock is based upon our restated certificate
March 26, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioAtla, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value pe
February 21, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Nu
February 14, 2024	SC 13G/A	BCAB / BioAtla, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 b111241sc13ga2.htm AMENDMENT NO. 2 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* BioAtla, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropria
February 12, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 06, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Nu
February 9, 2024	SC 13G/A	BCAB / BioAtla, Inc. / SHORT JAY M PHD - BIOATLA, INC. JAY SHORT 13G/A Passive Investment SC 13G/A 1 bioatla-jayshort13ga.htm BIOATLA, INC. JAY SHORT 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* BioAtla, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statem
February 6, 2024	SC 13G/A	BCAB / BioAtla, Inc. / ACORN BIOVENTURES, L.P. - BIOATLA, INC. Passive Investment SC 13G/A 1 p24-0352sc13ga.htm BIOATLA, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioAtla, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropria
January 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 BIOATLA, INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Numb
January 9, 2024	EX-99.1	Important Notices & Disclaimers This presentation (the “Presentation”) by BioAtla, Inc. (“we”, “us”, “our”, “BioAtla”, or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 EX-99.1 Exhibit 99.1 Conditionally Active Biologics: Transforming Cancer Therapy Corporate Presentation January 2024 Important Notices & Disclaimers This presentation (the “Presentation”) by BioAtla, Inc. (“we”, “us”, “our”, “BioAtla”, or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operati
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 BIOATLA, INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Numb
January 8, 2024	EX-3.1	Amended and Restated Bylaws of BioAtla, Inc. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF BIOATLA, INC. (the “Corporation”) As adopted on and effective as of January 5, 2024 ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place, which shall be fixed or subsequently changed any time by the v
December 13, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Nu
December 13, 2023	EX-99.1	BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types Exhibit 99.1 BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses Ongoing Phase 2 clinical study of monotherapy and in combination with a PD-1 inhibitor SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) — B
December 4, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Num
December 4, 2023	EX-99.1	Important Notices & Disclaimers This presentation (the “Presentation”) by BioAtla, Inc. (“we”, “us”, “our”, “BioAtla”, or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 EX-99.1 Exhibit 99.1 Phase 2 Trial of Mecbotamab Vedotin (BA3011), CAB-AXL-ADC, Alone or in Combination with Nivolumab in Patients with Non- Squamous NSCLC BA3011 AXL NSCLC December 4, 2023 BioAtla \| Overview 1 confidential Important Notices & Disclaimers This presentation (the “Presentation”) by BioAtla, Inc. (“we”, “us”, “our”, “BioAtla”, or the “Company”) contains “forward-looking statements” w
November 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 7, 2023	EX-99.1	BIOATLA REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS BIOATLA REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be presented at upcoming IASLC conference in early December and discussed at KOL event on December 4, 2023 – Observed new
August 1, 2023	EX-10.3	Form of Stock Option Agreement (50%) Exhibit 10.3 RESTRICTED STOCK UNIT AGREEMENT UNDER THE BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN THIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”) is between BioAtla, Inc., a Delaware corporation (the “Company”), and [] (the “Grantee”) and is made as of , 2020 (the “Grant Date”). RECITALS WHEREAS, the Company maintains the BioAtla, Inc. 2020 Equity Incentive Plan (as it may be amended and/or
August 1, 2023	EX-99.1	BIOATLA REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS BIOATLA REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) – Submitted Food & Drug Administration (FDA) meeting request for potentially registrational study of BA3011 in non-small cell lung cancer (NSCLC) stu
August 1, 2023	EX-10.2	Form of Stock Option Agreement (25%) Exhibit 10.2 RESTRICTED STOCK UNIT AGREEMENT UNDER THE BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN THIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”) is between BioAtla, Inc., a Delaware corporation (the “Company”), and [] (the “Grantee”) and is made as of , 2020 (the “Grant Date”). RECITALS WHEREAS, the Company maintains the BioAtla, Inc. 2020 Equity Incentive Plan (as it may be amended and/or
August 1, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2023 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 1, 2023	EX-10.1	Form of Stock Option Agreement Exhibit 10.1 [Employee Form] Stock Option No: See Carta STOCK OPTION AGREEMENT UNDER THE BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN THIS STOCK OPTION AGREEMENT (this “Agreement”) is between BioAtla, Inc., a Delaware corporation (the “Company”), and See Carta (the “Grantee”). RECITALS WHEREAS, the Company maintains the BioAtla, Inc. 2020 Equity Incentive Plan (as it may be amended and/or restated fro
August 1, 2023	10-Q	jay and car UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q jay and car UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
June 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 11, 2023	EX-99.1	BIOATLA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS BIOATLA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in 2H23 – On track for submitting a meeting request to the Food & Drug Administration (FDA) for the potentially registr
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
April 27, 2023	SC 13G	BCAB / BioAtla Inc / ACORN BIOVENTURES, L.P. - BIOATLA, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioAtla, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 09077B104 (CUSIP Number) April 20, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
April 24, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section (a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section (a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definiti
April 24, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 23, 2023	S-8	As filed with the Securities and Exchange Commission on March 23, 2023 As filed with the Securities and Exchange Commission on March 23, 2023 Registration No.
March 23, 2023	EX-99	BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS Exhibit 99.1 BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23 – Initiated the potentially registrational Phase 2, part 2 BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) stu
March 23, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioAtla, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value pe
March 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 23, 2023	EX-4	Description of Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 BioAtla, Inc. (“we,” “our,” “us,” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following summary of the terms of our common stock is based upon our restated certificate
March 23, 2023	EX-10	First Amendment to Master Clinical Trial Agreement between BioAtla, Inc. and Bristol-Myers Squibb Company Exhibit 10.24 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]. FIRST AMENDMENT TO MASTER CLINICAL TRIAL COLLABORATION AGREEMENT This First Amendment to the Master Clinical Trial Collaboration Agreement (this “F
March 23, 2023	EX-10	Amended and Restated BioAtla Director Compensation Policy Exhibit 10.31 BIOATLA, INC. DIRECTOR COMPENSATION POLICY (As amended and restated on December 16, 2022) Each member of the Board of Directors (the “Board”) of BioAtla, Inc. (the “Company”), who is not an employee of the Company (each such member, a “Non-Employee Director”), will receive the compensation described in this Director Compensation Policy (the “Director Compensation Policy”) for his or
March 23, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
February 27, 2023	SC 13G/A	BCAB / BioAtla Inc / SHORT JAY M PHD - BIOATLA - JAY SHORT SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* BioAtla, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
February 27, 2023	EX-99.1	BioAtla Announces Change in Executive Leadership EX-99.1 Exhibit 99.1 BioAtla Announces Change in Executive Leadership SAN DIEGO, February 27, 2023 – BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott Smith, will be leaving the Company to pursue a new opportu
February 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 BIOATLA, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 BIOATLA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or other jurisdiction of incorporation) (Commission File Nu
February 15, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 09, 2023 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Nu
February 14, 2023	SC 13G/A	BCAB / Bioatla Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 bcab28230sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioAtla, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropr
February 14, 2023	SC 13G/A	BCAB / Bioatla Inc / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 schedule13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* BioAtla, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
February 9, 2023	SC 13G/A	BCAB / Bioatla Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: BioAtla Inc. Title of Class of Securities: Common Stock CUSIP Number: 09077B104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1
February 6, 2023	SC 13G/A	BCAB / Bioatla Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* BioAtla, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077B104 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
January 13, 2023	CORRESP	11085 Torreyana Road San Diego, CA 92121 11085 Torreyana Road San Diego, CA 92121 January 13, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Arzhang Navai, Office of Life Sciences Re: BioAtla, Inc. Registration Statement on Form S-3 Filed January 6, 2023 File No. 333-269148 REQUEST FOR ACCELERATION OF EFFECTIVENESS Acceleration Request Requested Date:
January 9, 2023	SC 13D/A	BCAB / Bioatla Inc / Soleus Private Equity Fund I, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d425664dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) BioAtla, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 09077B104 (CUSIP Number) Soleus Private Equity GP I, LLC 104 Field Point Road, 2nd Floor Greenwich, CT 06830 Attn: Steve
January 6, 2023	EX-1.1	Open Market Sale AgreementSM dated as of January 6, 2023, between BioAtla, Inc. and Jefferies LLC Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM January 6, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: BioAtla, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common stock, par
January 6, 2023	S-3	As filed with the Securities and Exchange Commission on January 6, 2023 S-3 1 d366888ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on January 6, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOATLA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 85-1922320 (State or Other Jurisdiction of Incor
January 6, 2023	424B5	$100,000,000 Common Stock 424B5 1 d445645d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-262528 PROSPECTUS SUPPLEMENT (To Prospectus dated May 18, 2022) $100,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, dated January 6, 2023, relating to the sale of shares of our common stock offered by this pros
January 6, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 BIOATLA, INC. (Exact name of registrant as specified in its charter) Delaware 001-39787 85-1922320 (State or other jurisdiction of incorporation) (Commission File Numb
January 6, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BioAtla, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Car
January 6, 2023	EX-4.8	Form of Indenture EX-4.8 2 d366888dex48.htm EX-4.8 Exhibit 4.8 BioAtla, Inc. AND , as Trustee INDENTURE Dated as of Debt Securities Reconciliation and tie between Trust Indenture Act of 1939, as amended, and the Indenture Trust Indenture Act Section Indenture Section §310(a)(1) 6.8 (a)(2) 6.8 (b) 6.9 §312(a) 7.1 (b) 7.2 (c) 7.2 §313(a) 7.3 (b)(2) 7.3 (c) 7.3 (d) 7.3 §314(a) 7.4 (c)(1) 1.2 (c)(2) 1.2 (e) 1.2 §316(a)
November 7, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 BIOATLA, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 BIOATLA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or other jurisdiction of incorporation) (Commission File Num
November 7, 2022	EX-1.1	Underwriting Agreement, dated November 4, 2022, by and between BioAtla, Inc. and J.P. Morgan Securities LLC. EX-1.1 Exhibit 1.1 EXECUTION VERSION BIOATLA, INC. 9,745,128 Shares of Common Stock Underwriting Agreement November 4, 2022 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: BioAtla, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to J.P. Morgan Securities LLC, as underwriter (the “Underwriter”), an aggregate of 9,745,128 shares o
November 7, 2022	424B5	9,745,128 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-262528 PROSPECTUS SUPPLEMENT (To Prospectus dated May 18, 2022) 9,745,128 Shares Common Stock We are offering 9,745,128 shares of our common stock.
November 4, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 BIOATLA, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 BIOATLA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or other jurisdiction of incorporation) (Commission File Num
November 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
November 4, 2022	EX-99.1	AXL BA3011-002 (Phase 2 Part 1) - Disposition as of October 2022 24 patients enrolled 6 patients on-going with 0 scan (3 combo) Preliminary Data 2 patients not dosed yet 2 withdrawal of consent early, before the first scan 14 efficacy-evaluable patie EX-99.1 Exhibit 99.1 BA3011 Supplemental NSCLC and Sarcoma Data 10/2022 1 AXL BA3011-002 (Phase 2 Part 1) - Disposition as of October 2022 24 patients enrolled 6 patients on-going with 0 scan (3 combo) Preliminary Data 2 patients not dosed yet 2 withdrawal of consent early, before the first scan 14 efficacy-evaluable patients* ORR: 5/14 (36%) 12 Non-Sq patients 2 Sq patients ORR: 5/12 (42%) ORR: 0
November 4, 2022	EX-10.2	Master Clinical Trial Collaboration Agreement, dated January 5, 2022, by and between BioAtla, Inc. and Bristol-Myers Squibb Company Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***].” MASTER CLINICAL TRIAL COLLABORATION AGREEMENT This Master Clinical Trial Collaboration Agreement (the “Agreement”) is made and entered into as of a
November 3, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 3, 2022	EX-99.1	BIOATLA REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolled – BA3011 Undifferentiated BIOATLA REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolled – BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) enrollment in Phase 2 part 2 of study anticipated to begin by year-end – CAB-CTLA-4 (BA3071) Phase 1 study ongoing in tumor
September 21, 2022	EX-10.1	BioAtla, Inc. Management Change of Control Severance Plan BIOATLA, INC. MANAGEMENT CHANGE OF CONTROL SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION BIOATLA, INC. MANAGEMENT CHANGE OF CONTROL SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION BioAtla, Inc. (the ?Company?), and all of its U.S. based wholly owned subsidiaries (collectively, the ?Employer?) have established this BioAtla, Inc. Management Change of Control Severance Plan (the ?Plan?) with the intention
September 21, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File N
August 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2022 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 9, 2022	EX-10.1	China Clinical Trial Services Agreement, dated April 8, 2022, by and between BioAtla, Inc. and Himalaya Therapeutics Limited Company CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
August 9, 2022	EX-99.1	BIOATLA REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS BIOATLA REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Mecbotamab vedotin (BA3011) Phase 2 preliminary observations in Non-Small Cell Lung Carcinoma (NSCLC) supports advancing to the registrational stage of the study; anticipate full interim data set in 4Q22 – Mecbotamab vedotin (BA3011) Undifferentiated Pleomorphic Sarcoma (UPS) and osteosarcoma Phase 2 part 2 enro
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
June 17, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Number
June 6, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 17, 2022	POS AM	As filed with the Securities and Exchange Commission on May 17, 2022 As filed with the Securities and Exchange Commission on May 17, 2022 Registration No.
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
May 5, 2022	EX-10.1	BioAtla Director Compensation Policy Exhibit 10.1 BIOATLA, INC. DIRECTOR COMPENSATION POLICY (As amended and restated on February 22, 2022) Each member of the Board of Directors (the “Board”) of BioAtla, Inc. (the “Company”), who is not an employee of the Company (each such member, a “Non-Employee Director”), will receive the compensation described in this Director Compensation Policy (the “Director Compensation Policy”) for his or h
May 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2022 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 4, 2022	EX-99.1	BIOATLA REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS BIOATLA REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS ? Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma ? ? Mecbotamab vedotin (BA3011) Phase 2 interim analysis in NSCLC anticipated in first half 2022; interim update projected on 2Q22 earnings call ? ? Ozuriftamab vedotin (BA3021) NSCLC Phase 2 preliminary cohort enrollment completion and interim update anticipated in second half of 2022 ? ? Ozuriftamab vedotin (BA3021) SCCHN Phase 2 and BA3071 Phase 1 studies anticipate first patients dosed in second quarter of 2022 ? ? Cash balance of $219.
April 28, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of BioAtla, Inc. and further agree to the filing of this Joint Filing Agreement as an exhibit
April 28, 2022	SC 13G	BCAB / Bioatla Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
April 25, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 25, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14
April 11, 2022	EX-99.1	Important Notices & Disclaimers This presentation (the “Presentation”) by BioAtla, Inc. (“we”, “us”, “our”, “BioAtla”, or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 Exhibit 99.1 TRANSFORMING CANCER THERAPY April 2022 Needham & Co Annual Healthcare Conference 1 ` Important Notices & Disclaimers This presentation (the ?Presentation?) by BioAtla, Inc. (?we?, ?us?, ?our?, ?BioAtla?, or the ?Company?) contains ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial c
April 11, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 BIOATLA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or other jurisdiction of incorporation) (Commission File Numbe
March 1, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioAtla, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value pe
March 1, 2022	424B3	BioAtla, Inc. Up to 2,678,600 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-260440 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated November 3, 2021) BioAtla, Inc. Up to 2,678,600 Shares of Common Stock This prospectus supplement supplements the prospectus dated November 3, 2021 (the ?Prospectus?), which forms a part of our registration statement on Form S-1 (No. 333-260440). This prospectus supplemen
March 1, 2022	POS AM	As filed with the Securities and Exchange Commission on March 1, 2022 POS AM 1 d160810dposam.htm POS AM Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. 333-262528 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOATLA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 8
March 1, 2022	S-8	As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No.
February 28, 2022	EX-10.22	Offer Letter between BioAtla, LLC and Christian Vasquez, dated October 22, 2015 Exhibit 10.22 BIOATLA, LLC 11011 Torreyana Road San Diego, CA 92121 October 22, 2015 Christian J. Vasquez Re: Offer of Employment Dear Chris: I am pleased to offer you employment with BioAtla, LLC, a Delaware limited liability company ("Company"). Once signed by you, this Offer Letter will confirm your acceptance of the following terms and conditions: 1. Your title will be Corporate Controller. Yo
February 28, 2022	EX-10.27	Amendment No. 1 to Employee Share Purchase Plan Exhibit 10.27 AMENDMENT #1 TO BIOATLA, INC. EMPLOYEE STOCK PURCHASE PLAN Pursuant to the authority reserved to it in Section 20 of the BioAtla, Inc. 2020 Employee Stock Purchase Plan, adopted December 7, 2020 and as amended from time to time (the ?Plan?), the Board of Directors of BioAtla, Inc. (the ?Board?) hereby amends the Plan as follows, effective September 14, 2021: 1. Section 4(a) of the Pl
February 28, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 28, 2022	EX-10.20	Severance Agreement between BioAtla, LLC and Richard Waldron, dated July 1, 2018 Exhibit 10.20 BioAtla, LLC Effective July l, 2018 Richard Waldron c/o BioAtla, LLC Re: Severance Agreement Dear Richard, BioAtla, LLC (the "Company"), is pleased to provide the following Severance Agreement (the "Agreement") to you. This Agreement will be effective only if you sign and return this Agreement within ten (10) business days. 1. Eligibility / Change in Control Severance Benefits. If (i
February 28, 2022	EX-10.21	Offer Letter between BioAtla, LLC and Eric Sievers, dated June 17, 2019 Exhibit 10.21 June 17, 2019 Eric Sievers, MD [*] [*] Dear Eric: On behalf of BioAtla LLC (the "Company"), I am pleased to confirm the terms of your employment offered by the Company. 1. Position: is a full-time position as Chief Medical Officer (CMO), an officer of the Company reporting to Scott Smith, President. 2. Work Location: Your principal place of employment will be the Company's office
February 28, 2022	EX-10.31	BioAtla Director Compensation Policy Exhibit 10.31 bioatla, INC. DIRECTOR COMPENSATION POLICY (Adopted and approved on December 15, 2021) Each member of the Board of Directors (the ?Board?) of BioAtla, Inc. (the ?Company?), who is not an employee of the Company (each such member, a ?Non-Employee Director?), will receive the compensation described in this Director Compensation Policy (the ?Director Compensation Policy?) for his or her
February 28, 2022	EX-10.26	Amendment No. 2 to 2020 Equity Incentive Plan Exhibit 10.26 AMENDMENT #2 TO BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN Pursuant to the authority reserved to it in Section 9.1 of the BioAtla, Inc. 2020 Equity Incentive Plan, adopted October 29, 2020 and as amended from time to time (the ?Plan?), the Board of Directors of BioAtla, Inc. (the ?Board?) hereby amends the Plan as follows, effective September 14, 2021: 1. Section 6.1(c) of the Plan is
February 28, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BioAtla, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fe
February 28, 2022	EX-10.19	Offer Letter between BioAtla, LLC and Richard Waldron, dated October 23, 2013 Exhibit 10.19 BIOATLA, LLC 11085 Torreyana Rd. San Diego, CA 92121 October 21, 2013 Richard Waldron [*] [*] Re: Offer of Employment Dear Richard: I am pleased to offer you employment with BioAtla, LLC, a Delaware limited liability company ("Company"). Once signed by you, this Offer Letter will confirm your acceptance of the following terms and conditions: 1. Your title will be Chief Financial
February 28, 2022	POSASR	As filed with the Securities and Exchange Commission on February 28, 2022 POSASR 1 d216033dposasr.htm POSASR Table of Contents As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. 333-262528 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOATLA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaw
February 28, 2022	EX-10.28	Amendment No. 3 to Global Co-Development and Collaboration Agreement between BioAtla, Inc. and BeiGene, Ltd Exhibit 10.28 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRVIATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***].? AMENDMENT NO. 3 TO GLOBAL CO-DEVELOPMENT AND COLLABORATION AGREEMENT THIS AMENDMENT NO. 3 TO GLOBAL CO-DEVELOPMENT AND COLLABORATION AGREEMENT (this ?Amendment?)
February 28, 2022	EX-4.3	Exhibit 4.3 Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 BioAtla, Inc. (?we,? ?our,? ?us,? or the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following summary of the terms of our common stock is based upon our restated certificate
February 25, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2022 BIOATLA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or other jurisdiction of incorporation) (Commission File Nu
February 14, 2022	SC 13G/A	BCAB / Bioatla Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* BioAtla, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
February 14, 2022	SC 13G/A	BCAB / Bioatla Inc / SHORT JAY M PHD - JAY SHORT 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioAtla, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
February 11, 2022	SC 13G/A	BCAB / Bioatla Inc / PFIZER INC - SC 13G/A BIOATLA Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) 1 BioAtla, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 2021 (
February 11, 2022	SC 13G/A	BCAB / Bioatla Inc / HBM Healthcare Investments (Cayman) Ltd. - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioAtla, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
February 9, 2022	SC 13G	BCAB / Bioatla Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0410-bioatlainc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: BioAtla Inc. Title of Class of Securities: Common Stock CUSIP Number: 09077B104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Sch
February 8, 2022	SC 13G/A	BCAB / Bioatla Inc / FARALLON CAPITAL MANAGEMENT LLC - AMENDMENT #1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 4, 2022	S-3ASR	Power of Attorney (included on the signature page to this registration statement) Table of Contents As filed with the Securities and Exchange Commission on February 4, 2022 Registration No.
February 4, 2022	SC 13G	BCAB / Bioatla Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioAtla, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i
February 4, 2022	EX-4.8	Form of Indenture Exhibit 4.8 BIOATLA, INC. AND , as Trustee, INDENTURE Dated as of Debt Securities Reconciliation and tie between Trust Indenture Act of 1939, as amended, and the Indenture Trust Indenture Act Section Indenture Section (S)310(a)(1) 6.8 (a)(2) 6.8 (b) 6.9 (S)312(a) 7.1 (b) 7.2 (c) 7.2 (S)313(a) 7.3 (b)(2) 7.3 (c) 7.3 (d) 7.3 (S)314(a) 7.4 (c)(1) 1.2 (c)(2) 1.2 (e) 1.2 (f) 1.2 (S)316(a) (last sentenc
February 4, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BioAtla, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title(1)(2) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registrat
January 11, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2022 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Num
January 11, 2022	EX-99.1	BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo Exhibit 99.1 BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo?(nivolumab) for Treatment of Solid Tumors SAN DIEGO, CA ? January 10, 2022 - BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) anti
December 21, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Nu
December 21, 2021	EX-99.1	BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS Exhibit 99.1 BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS SAN DIEGO, CA ? December 21, 2021?BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committ
November 19, 2021	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2021 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
November 15, 2021	EX-10.2	Form of Employee Stock Option Agreement Exhibit 10.2 Stock Option No: See Carta STOCK OPTION AGREEMENT UNDER THE BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN THIS STOCK OPTION AGREEMENT (this ?Agreement?) is between BioAtla, Inc., a Delaware corporation (the ?Company?), and See Carta (the ?Grantee?). RECITALS WHEREAS, the Company maintains the BioAtla, Inc. 2020 Equity Incentive Plan (as it may be amended and/or restated from time to time,
November 15, 2021	EX-10.1	Form of Non-Employee Director Stock Option Agreement Exhibit 10.1 Stock Option No: See Carta STOCK OPTION AGREEMENT UNDER THE BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN THIS STOCK OPTION AGREEMENT (this ?Agreement?) is between BioAtla, Inc., a Delaware corporation (the ?Company?), and See Carta (the ?Grantee?). RECITALS WHEREAS, the Company maintains the BioAtla, Inc. 2020 Equity Incentive Plan (as it may be amended and/or restated from time to time,
November 3, 2021	424B3	2,678,600 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-260440 2,678,600 Shares Common Stock This prospectus relates to the resale, from time to time, of up to 2,678,600 shares of our common stock by the selling stockholders (which term, as used in this prospectus, includes pledgees, donees, transferees or other successors-in-interest) identified in this prospectus. The selling sto
November 1, 2021	CORRESP	11085 Torreyana Road San Diego, CA 92121 11085 Torreyana Road San Diego, CA 92121 November 1, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Joseph McCann, Office of Life Sciences Re: BioAtla, Inc. Registration Statement on Form S-1 Filed October 22, 2021 File No. 333-260440 REQUEST FOR ACCELERATION OF EFFECTIVENESS Acceleration Request Requested Date
October 22, 2021	S-1	As filed with the Securities and Exchange Commission on October 22, 2021 Table of Contents As filed with the Securities and Exchange Commission on October 22, 2021 Registration No.
September 29, 2021	EX-99.1	BIOATLA ANNOUNCES PRIVATE PLACEMENT OF 2.7 MILLION SHARES Proceeds to advance CAB-AXL and CAB-ROR2 through potentially registration enabling Phase 2 clinical trials, and additional CAB development programs Exhibit 99.1 BIOATLA ANNOUNCES PRIVATE PLACEMENT OF 2.7 MILLION SHARES Proceeds to advance CAB-AXL and CAB-ROR2 through potentially registration enabling Phase 2 clinical trials, and additional CAB development programs SAN DIEGO, CA ? September 29, 2021 - BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) an
September 29, 2021	EX-4.1	Form of Stock Purchase Agreement Exhibit 4.1 FORM OF STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this ?Agreement?) is made as of September 28, 2021 (the ?Effective Date?) by and between BioAtla, Inc., a Delaware corporation (the ?Company?), and [] (?Purchaser?). 1. Issuance of Shares. Effective as the Effective Date, the Company agrees to issue and sell to Purchaser [] shares (the ?Shares?) of the Company?s Common Sto
September 29, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2021 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File N
September 3, 2021	SC 13D/A	BCAB / Bioatla Inc / Soleus Private Equity Fund I, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) BioAtla, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 09077B104 (CUSIP Number) Soleus Private Equity GP I, LLC 104 Field Point Road, 2nd Floor Greenwich, CT 06830 Attn: Steven J. Musumeci (475) 208-3178 (
August 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
June 28, 2021	SC 13D/A	BCAB / Bioatla Inc / Soleus Private Equity Fund I, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d136087dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) BioAtla, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 09077B104 (CUSIP Number) Soleus Private Equity GP I, LLC 104 Field Point Road, 2nd Floor Greenwich, CT 06830 Attn: Steve
June 17, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39787 85-1922320 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 12, 2021	EX-10.1	Transition Agreement by and between BioAtla, Inc. and Carolyn Anderson Short, dated March 23, 2021. Exhibit 10.1 TRANSITION AGREEMENT This Transition Agreement (?Agreement?) is made and entered into between Carolyn Anderson Short (?Executive?) and BioAtla, Inc. (?BioAtla? or the ?Company?). 1. SEPARATION. The parties agree that the employment relationship between Executive and BioAtla will transition and end as set forth in this Agreement. 2. TRANSITION PERIOD. The parties agree that Executive w
May 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 BIOATLA, INC.
April 30, 2021	DEF 14A	- DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14
April 30, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
March 24, 2021	EX-4.3	Description of Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 BioAtla, Inc. (?we,? ?our,? ?us,? or the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following summary of the terms of our common stock is based upon our restated certificate
March 24, 2021	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-3978
March 24, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 24, 2021 Registration No.
February 16, 2021	EX-99.1	JOINT FILING AGREEMENT CUSIP No. 09077B104 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit 99.1, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Dated: February 12, 2021 PFIZER INC. By: /s/ Su
February 16, 2021	EX-1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of BioAtla, Inc.
February 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. __)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioAtla, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 09077B104 (CUSIP Number) February 16, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioAtla, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
February 16, 2021	SC 13G	(Amendment No. ) * CUSIP No. 09077B104 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * BioAtla, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 09077B104 (CUSIP Number) December 31, 20
February 9, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2021 BioAtla, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39787 85-1922320 (State or other jurisdiction of incorporation) (Commission File
December 28, 2020	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
December 28, 2020	SC 13D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.) BioAtla, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) (CUSIP Number SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.) BioAtla, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 09077B104 (CUSIP Number) Soleus Private Equity GP I, LLC 104 Field Point Road, 2nd Floor Greenwich, CT 06830 Attn: Steven J. Musumeci (475) 208-3178 (Name,
December 28, 2020	EX-99.1	JOINT FILING AGREEMENT EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of the Issuer and further agree that this Joint Filing Agreement be included as an Exhibit to such j
December 28, 2020	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioAtla, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077B104 (CUSIP Number) December 18, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i
December 28, 2020	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of December 28, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with
December 28, 2020	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioAtla, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09077B104 (CUSIP Number) December 15, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
December 18, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2020 BioAtla, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39787 85-1922320 (State or other jurisdiction of incorporation) (Commission Fil
December 18, 2020	EX-3.1	Amended and Restated Certificate of Incorporation of BioAtla, Inc. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOATLA, INC. BioAtla, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is BioAtla, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was
December 18, 2020	S-8	Form S-8 S-8 As filed with the Securities and Exchange Commission on December 18, 2020 Registration No.
December 18, 2020	EX-3.2	Amended and Restated Bylaws of BioAtla, Inc. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF BIOATLA, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may subs
December 18, 2020	EX-99.2	Amendment No. 1 to 2020 Equity Incentive Plan EX-99.2 Exhibit 99.2 AMENDMENT 1 TO BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN Pursuant to the authority reserved to it in Section 9.1 of the BioAtla, Inc. 2020 Equity Incentive Plan, adopted October 29, 2020 and as amended from time to time (the “Plan”), the Board of Directors of BioAtla, Inc. (the “Board”) hereby amends the Plan as follows, effective December 7, 2020: 1. Section 5.1 of the Plan is
December 17, 2020	424B4	See accompanying notes. 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-250093 Registration No. 333-251373 Prospectus 10,500,000 shares Common stock This is an initial public offering of shares of common stock by BioAtla, Inc. We are offering 10,500,000 shares of our common stock. The initial public offering price of our common stock is $18.00 per share. Prior to this offering, there has bee
December 15, 2020	S-1MEF	- S-1MEF S-1MEF As filed with the Securities and Exchange Commission on December 15, 2020 Registration No.
December 11, 2020	CORRESP	December 11, 2020 December 11, 2020 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.
December 11, 2020	CORRESP	[Signature Page Follows] December 11, 2020 BY EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Deanna Virginio Suzanne Hayes Nudrat Salik Sasha Parikh Re: BioAtla, Inc. Registration Statement Filed on Form S-1 File No. 333-250093 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amen
December 9, 2020	8-A12B	Form 8-A 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 BioAtla, Inc. (Exact name of registrant as specified in its charter) Delaware 85-1922320 (State of incorporation or organization) (IRS Employer Identification No.) 11085 Torreyana Road San D
December 9, 2020	S-1/A	- S-1/A S-1/A Table of Contents As filed with the Securities and Exchange Commission on December 9, 2020 Registration No.
December 9, 2020	CORRESP	* * * December 9, 2020 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
December 8, 2020	EX-4.2	Investors’ Rights Agreement, dated July 13, 2020 EX-4.2 Exhibit 4.2 INVESTORS’ RIGHTS AGREEMENT THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 13th day of July, 2020, by and among BioAtla, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the direct and indirect beneficial owners of the Company’s Comm
December 8, 2020	EX-4.4	Voting Agreement, dated July 13, 2020 EX-4.4 Exhibit 4.4 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of this 13th day of July, 2020, by and among BioAtla, Inc., a Delaware corporation (the “Company”), each holder of the Company’s Series D Preferred Stock, $0.0001 par value per share (“Series D Preferred Stock”) (also referred to herein as the “Preferred Stock”), listed on Schedule A (together
December 8, 2020	EX-4.3	Right of First Refusal and Co-Sale Agreement, dated July 13, 2020 EX-4.3 Exhibit 4.3 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT THIS RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (this “Agreement”) is made as of the 13th day of July, 2020 by and among BioAtla, Inc., a Delaware corporation (the “Company”), the Investors listed on Schedule A and the Key Holders listed on Schedule B. RECITALS: WHEREAS, each Key Holder is the direct or indirect beneficial owner of
December 8, 2020	CORRESP	* * * December 8, 2020 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
December 8, 2020	EX-10.13	Severance Agreement between BioAtla, LLC and Jay Short, dated July 1, 2018 EX-10.13 Exhibit 10.13 BioAtla, LLC Effective July l, 2018 Jay M. Short, PhD C/o BioAtla, LLC Re: Severance Agreement Dear Jay, BioAtla, LLC (the “Company”), is pleased to provide the following Severance Agreement (the “Agreement”) to you. This Agreement will be effective only if you sign and return this Agreement within ten (10) business days. 1. Eligibility / Severance Benefits. If (i) your empl
December 8, 2020	EX-10.14	Offer Letter between BioAtla, LLC and Scott Smith, dated August 2, 2018 EX-10.14 Exhibit 10.14 August 2, 2018 Mr. Scott Smith 100 Barclay Street, 17L New York, NY 10007 Dear Scott: On behalf of BioAtla LLC (the “Company”), I am pleased to confirm the terms of your employment offered by the Company in connection with your role as President of the Company. 1. Position: Your employment as President shall be a full-time position as an officer of the Company reporting to t
December 8, 2020	EX-1.1	Form of Lock-Up Agreement (included as Exhibit D to the form of Underwriting Agreement filed as Exhibit 1.1 to the Registration Statement on Form S-1 (No. 333-250093) of the Issuer, and incorporated herein by reference). EX-1.1 Exhibit 1.1 BIOATLA, INC. [●] Shares of Common Stock Underwriting Agreement December [●], 2020 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Jefferies LLC 520 Madison Avenue New York, New York 10022 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010 As Representatives of the several Underwriters listed in Schedule 1 hereto Ladies and G
December 8, 2020	EX-10.1	2020 Equity Incentive Plan EX-10.1 Exhibit 10.1 BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN Section 1. Purpose of the Plan. The purpose of the BioAtla, Inc. 2020 Equity Incentive Plan (the “Plan”) is to assist the Company and its Subsidiaries in attracting and retaining valued Employees, Consultants and Non-Employee Directors by offering them a greater stake in the Company’s success and a closer identity with it, and to encour
December 8, 2020	EX-10.11	Employment Letter Agreement between BioAtla, LLC and Jay Short, as amended by the Letter Amendment dated October 1, 2011 EX-10.11 Exhibit 10.11 Short Employment Letter Agreement This letter agreement (“Agreement”) memorializes a verbal agreement discussed as noted between the members of BioAtla LLC (“BioAtla”), a Delaware company, and Dr. Jay M. Short (“Dr. Short”), it’s Chairman and Chief Executive Officer. 1. For his roll as Chairman & Chief Executive Officer of BioAtla, beginning April 2nd, 2007, Dr. Jay M. Short
December 8, 2020	EX-10.2	Form of Restricted Stock Agreement EX-10.2 Exhibit 10.2 RESTRICTED STOCK UNIT AGREEMENT UNDER THE BIOATLA, INC. 2020 EQUITY INCENTIVE PLAN THIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”) is between BioAtla, Inc., a Delaware corporation (the “Company”), and [ ] (the “Grantee”) and is made as of [ ], 2020 (the “Grant Date”). RECITALS WHEREAS, the Company maintains the BioAtla, Inc. 2020 Equity Incentive Plan (as it may be ame
December 8, 2020	EX-10.3	2020 Employee Stock Purchase Plan EX-10.3 Exhibit 10.3 BIOATLA, INC. EMPLOYEE STOCK PURCHASE PLAN Adopted by the Board of Directors December 7, 2020 Approved by the Stockholders December 7, 2020 BIOATLA, INC. EMPLOYEE STOCK PURCHASE PLAN SECTION 1. PURPOSE OF THE PLAN. The BioAtla, Inc. Employee Stock Purchase Plan (the “Plan”) is intended to provide Eligible Employees (as defined below) the opportunity to increase their proprieta
December 8, 2020	EX-3.2	Form of Amended and Restated Certificate of Incorporation of BioAtla, Inc., to be effective upon the completion of this offering EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOATLA, INC. BioAtla, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is BioAtla, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was
December 8, 2020	EX-4.1	Specimen Common Stock Certificate evidencing the shares of common stock EX-4.1 Exhibit 4.1
December 8, 2020	EX-10.17	Severance Agreement between BioAtla, LLC and Carolyn Short, as amended by the Amended Severance Agreement between BioAtla, LLC and Carolyn Short, dated April 1, 2020 EX-10.17 Exhibit 10.17 BioAtla, I.LC Effective April 1st, 2020 Carolyn Short c/o BioAtla, LLC Re: Severance Agreement April 2020 Dear Carolyn Short, BioAtla, LLC (the “Company-), is pleased to provide the following Amended Severance Agreement (the -Agreement”) to you (the “Executive”). This Agreement will be effective only if you sign and return this Agreement within ten (10) business days. 1. Eli
December 8, 2020	EX-10.16	Severance Agreement between BioAtla, LLC and Scott Smith, dated August 20, 2018 EX-10.16 Exhibit 10.16 BioAtla, LLC August 20th, 2018 Scott Smith c/o BioAtla, LLC Re: Severance Agreement Dear Scott, BioAtla, LLC (the “Company”), is pleased to provide the following Severance Agreement (the “Agreement”) to you. This Agreement will be effective only if you sign and return this Agreement within ten (10) business days. 1. Eligibility / Change in Control Severance Benefits. If (i)
December 8, 2020	EX-3.3	Bylaws of BioAtla, Inc., as currently in effect EX-3.3 Exhibit 3.3 BYLAWS OF BIOATLA, INC. ARTICLE I Meetings of Stockholders Section 1.1. Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be designated by resolution of the Board of Directors from time to time. Any other proper
December 8, 2020	EX-3.4	Form of Amended and Restated Bylaws of BioAtla, Inc., to be effective upon the completion of this offering EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF BIOATLA, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may subs
December 8, 2020	EX-10.12	Offer Letter between BioAtla, LLC and Carolyn Short, dated November 30, 2015 EX-10.12 Exhibit 10.12 November 30, 2015 Carolyn Anderson Short 12985 Via Esperia Del Mar, CA 92114 Re: Offer of Employment Dear Carolyn: I am pleased to offer you employment with BioAtla, LLC, Delaware limited liability company (“Company”). Once signed by you, this Offer Letter will confirm your acceptance of the following terms and conditions: 1. Your title will be Chief of IP and Strategy. Your
December 8, 2020	EX-10.15	Letter Agreement between BioAtla, LLC and Scott Smith, dated August 3, 2018 EX-10.15 Exhibit 10.15 August 3, 2018 Mr. Scott Smith 100 Barclay Street, 17L New York, NY 10007 Dear Scott: We are excited at the prospect of your agreement to the BioAtla LLC offer letter dated August 2, 2018. I wish to clarify an important provision related to the Profits Interests and NewCo equity elements in paragraph 6 of the letter copied here in entirety for convenient reference: Profits I
December 8, 2020	S-1/A	- S-1/A S-1/A Table of Contents As filed with the Securities and Exchange Commission on December 8, 2020 Registration No.
December 8, 2020	EX-3.1	Certificate of Incorporation of BioAtla, Inc., as currently in effect EX-3.1 Exhibit 3.1 CERTIFICATE OF INCORPORATION OF BIOATLA, INC. The undersigned, for the purposes of incorporating and organizing a corporation under the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby execute this Certificate of Incorporation and does hereby certify as follows: FIRST: The name of this corporation is BioAtla, Inc. (the “Corporation”).
December 8, 2020	EX-10.19	Lease Agreement with HCP Torreyana, LLC, dated June 2, 2017, as amended by First Amendment to Lease, dated January 16, 2019 EX-10.19 Exhibit 10.19 11085 TORREYANA ROAD LEASE This Lease (this “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HCP TORREYANA, LLC, a Delaware limited liability company (“Landlord”), and BIOATLA, LLC, a Delaware limited liability company (“Tenant”). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEASE DE
December 8, 2020	EX-10.18	Form of Indemnification Agreement between the Registrant and each of its executive officers EX-10.18 Exhibit 10.18 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [•], 2020, between BioAtla, Inc., a Delaware corporation (the “Company”), and [name] (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in other capacities unless they are provided

BCAB / BioAtla, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)